--- title: "Axogen (AXGN) stock listing, news and investor profile" url: "https://aibio.space/companies/axogen/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Axogen, Inc. (NASDAQ: AXGN), United States. Listing facts, related biotech companies and news on aibio.space." --- AXGN Axogen, Inc. NASDAQ · United States # Axogen (AXGN) news Axogen, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AXGN, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Axogen news We have not published a story on Axogen yet. When there is news, it will appear here. ## Axogen at a glance - **Ticker**: AXGN - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $348.1 million ### Related companies - [ARTIVION, INC.](https://aibio.space/companies/artivion/) NYSE: AORT - [FAMILY OFFICE OF AMERICA, INC.](https://aibio.space/companies/family-office-of-america/) OTC: FOFA - [SI-BONE](https://aibio.space/companies/si-bone/) NASDAQ: SIBN - [INTEGRA LIFESCIENCES HOLDINGS CORP](https://aibio.space/companies/integra-lifesciences/) NASDAQ: IART - [Nu-Med Plus](https://aibio.space/companies/nu-med-plus/) OTC: NUMD - [Flyte Aviation](https://aibio.space/companies/flyte-aviation/) NYSE: VJET - [GLOBUS MEDICAL INC](https://aibio.space/companies/globus-medical/) NYSE: GMED - [LEMAITRE VASCULAR INC](https://aibio.space/companies/lemaitre-vascular/) NASDAQ: LMAT ### Also on NASDAQ - [Scilex Holding](https://aibio.space/companies/scilex/) SCLX - [Spruce Biosciences](https://aibio.space/companies/spruce-biosciences/) SPRB - [NEUROONE MEDICAL TECHNOLOGIES](https://aibio.space/companies/neuroone-medical-technologies/) NMTC - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) BFRI - [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) REGN - [Coya Therapeutics](https://aibio.space/companies/coya-therapeutics/) COYA ## Axogen annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$225.2 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | [$187.3 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | | Research and development | [$32.9 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | [$27.8 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | | Net income (loss) | [-$15.7 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | [-$10.0 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | | Cash from operations | [$812,000](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | [$4.5 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | | Cash and equivalents | [$35.5 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000108/) | [$27.6 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | | Short-term investments | [$6.0 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000108/) | [$5.9 million](https://www.sec.gov/Archives/edgar/data/805928/000080592826000031/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $328.9 million, plus short-term investments of $19.2 million, $348.1 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Axogen What is the ticker symbol of Axogen? Axogen, Inc. trades under the ticker AXGN on NASDAQ. Where is Axogen listed? Axogen, Inc. is listed on NASDAQ. Which country or territory is Axogen listed under? Our directory records Axogen, Inc. under United States. Does aibio.space cover Axogen? aibio.space lists Axogen, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What was Axogen's revenue last year? $225.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Axogen profitable? Axogen, Inc. reported a net loss of $15.7 million for the fiscal year ended Dec 31, 2025, and generated $812,000 of cash from operations, per its annual report to the SEC. How much does Axogen spend on research and development? $32.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Axogen have? $348.1 million in cash and short-term investments at Sep 30, 2026, per its 10-Q. ## Investor discussion: Axogen Members talk about Axogen (AXGN). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Axogen, newest first. Each line links the filing it comes from. 1. 2026-09-10 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/805928/000162828026061208/exhibit991-8xk09102026.htm) 2. 2026-09-10 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/805928/000162828026061394/axogen-424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:AXGN on TradingView](https://www.tradingview.com/symbols/NASDAQ-AXGN/). ## Listing details Axogen, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AXGN, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Axogen, Inc. - **Ticker**: AXGN - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/axogen/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Axogen (AXGN) stock listing, news and investor profile", 2026-10-31, https://aibio.space/companies/axogen/